Yu Liang - Publications

Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.

Journal: Biochemical and biophysical research communications

Published: May 13, 2026

Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation.

Journal: Science (New York, N.Y.)

Published: September 26, 2024

Fluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: January 17, 2024

Chimeric virus-like particles of human norovirus constructed by structure-guided epitope grafting elicit cross-reactive immunity against both GI.1 and GII.4 genotypes.

Journal: Journal of virology

Published: October 04, 2023

Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus.

Journal: NPJ vaccines

Published: August 01, 2023

Modeling COVID-19 transmission dynamics incorporating media coverage and vaccination.

Journal: Mathematical biosciences and engineering : MBE

Published: June 16, 2023

Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant.

Journal: Journal of molecular graphics & modelling

Published: November 28, 2022

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: September 14, 2022

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.

Journal: eLife

Published: March 14, 2022

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.

Journal: Nature communications

Published: February 17, 2022

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: January 12, 2022

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.

Journal: Frontiers of medicine

Published: December 09, 2021